Predictive Diagnostics

SHL Medical and Lifecore Biomedical enter co-marketing partnership agreement

SHL Medical ("SHL"), a world-leading solutions provider of advanced drug delivery systems such as autoinjectors and innovative specialty delivery systems, has entered into a non-exclusive co-marketing partnership agreement with Lifecore Biomedical (Nasdaq: LFCR) ("Lifecore"), a fully integrated Contract Development and Manufacturing Organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in sy...

BGI Genomics Combats Hepatitis in Ethiopia

Healthcare localization and standardization support the Belt and Road Initiative...

GE Healthcare Gets FDA Clearance for Allia IGS Pulse: Next-Gen Cardiac Imaging System

GE HealthCare (Nasdaq: GEHC) announced US FDA 510(k) clearance of Allia IGS Pulse - the latest addition to the company’s image guided system (IGS) offerings. Allia IGS Pulse features a new imaging chain engineered to provide exceptional imaging at the right dose for visible impact in complex cardiology interventions regardless of patient size....

IIT-D ( India ) designs scalable wearable pressure sensor to analyse gait patterns and postural deformities

Sensor can potentially provide an easy, low-cost alternative to expensive footwear modifications...

Shaping the Future of Anaesthesia and Critical Care in India: An Exclusive Interview with Shalin Patel, Managing Director of Draeger India Group

On the occasion of World Anaesthesia Day, MedTech Spectrum & BioSpectrum India delve into the dynamic world of healthcare and technological innovation. We had the privilege of speaking with Mr. Shalin Patel, the Managing Director of Draeger India Group, a prominent player in the medical and safety technology sector....

Boston Scientific Gets FDA Nod for Spinal Cord Stimulation in Diabetic Neuropathy

Nearly 50% of American adults living with diabetes will be affected by diabetic neuropathy complications in their lifetime...

Roche's Fenebrutinib Shows Brain Penetration and Lesion Reduction in Multiple Sclerosis Patients: Late-breaking Data

Roche announced new data from the Phase II FENopta study showing that investigational, oral fenebrutinib is brain penetrant and reduces brain lesions in people with relapsing multiple sclerosis (RMS) with a consistent safety profile to other fenebrutinib trials. The late-breaking data were featured in an oral presentation at the 9th Joint ECTRIMS-ACTRIMS Meeting (European and Americas Committees for Treatment and Research in Multiple Sclerosis)....

DELFI Diagnostics Introduces FirstLook Lung: A Breakthrough in Blood-Based Lung Cancer Screening

FirstLook Lung uses a breakthrough technology of whole-genome machine learning to analyze fragments of cell-free DNA that are markers of cancer in the blood...

Mylab transforms new-born screening with breakthrough point-of-care solution

Newborn screening is a critical public health program involving the testing of newborn infants for specific genetic, metabolic, and congenital disorders shortly after birth ...